Page 1111 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

32. Guilarde AO, Turchi MD, Siqueira Jr JB, et al. Dengue and 52. Fernandes GC, Camacho LAB, Carvalho MS, et al. Neurological
dengue hemorrhagic fever among adults: clinical outcomes adverse events temporally associated to mass vaccination against
related to viremia, serotypes, and antibody response. J Inf Dis. yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine. 2007;25:
2008;197:817-824. 3124-3128.
33. Murgue B. Severe dengue: questioning the paradigm. Microbes 53. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ
Infect. 2010;12:113-118. failure associated with 17D-204 yellow fever vaccination: a
34. Guzman MG, Kouri G. Dengue and dengue hemorrhagic report of four cases. Lancet 2001;358:98-104. Seminal article.
fever in the Americas: lessons and challenges. J Clin Virol. 54. Hayes EB. Acute viscerotropic disease following vacci-
2003;27:1-13. nation against yellow fever. Trans Roy Soc Trop Med Hyg.
35. Guzman A, Istúriz RE. Update on the global spread of dengue. 2007;101:967-971.
Int J Antimicrob Agents. 2010;36S:S40-S42. 55. Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure
36. Teixeira MG, Barreto ML. Diagnosis and management of due to yellow fever vaccine-associated viscerotropic disease.
dengue. BMJ. 2009;339:1189-1193. Vaccine. 2007;25:8480-8485.
37. Ranjit S, Kissoon N. Dengue hemorrhagic fever and shock 56. Barrett ADT, Teuwen DE. Yellow fever vaccine-how does it
syndromes. Pediatr Crit Care Med. 2011;12:90-100. work and why do rare cases of serious adverse events take place?
Cur Opin Immunol. 2009;21:308-313.
38. Lee IK, Lee WH, Liu JW, et al. Acute myocarditis in den-
gue hemorrhagic fever: a case report and review of cardiac 57. Eidex RB, Yellow Fever Vaccine Safety Working Group. History
complications in dengue-affected patients. Int J Infect Dis. of thymoma and yellow fever vaccination. Lancet. 2004;364:936.
2010;14:e919-e922. 58. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine:
an updated assessment of advanced age as a risk factor for seri-
39. World Health Organization. Dengue Hemorrhagic Fever:
Diagnosis, Treatment, Prevention and Control. 2nd ed. Geneva: ous adverse events. Vaccine. 2005;23:3256-3263.
WHO; 1997:ISBN 9241545003. 59. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports
40. Narvaez F, Gutierrez G, Perez MA, et al. Evaluation of the following yellow fever vaccination. Vaccine. 2008;26:6077-6082.
traditional and revised WHO classifications of dengue disease 60. Ruzek D, Yakimenko VV, Karan LS, et al. Omsk hemorrhagic
severity. PLoS Negl Trop Dis. 2011;5:e1397. fever. Lancet. 2010;376:2104-2113. Seminal article.
41. Wang SM, Sekaran SD. Evaluation of a commercial SD dengue 61. Pattnaik P. Kyasanur forest disease: an epidemiological view in
virus NS1 antigen capture enzyme-linked immunosorbent assay India. Rev Med Virol. 2006;16:151-165.
kit for early diagnosis of dengue virus infection. J Clin Microbiol. 62. Mehla R, Kumar SRP, Yadav P, et al. Recent ancestry of Kyasanur
2010;48(8):2793-2797. Forest disease virus. Emerg Inf Dis. 2009;15:1431-1437.
42. World Health Organization. Guidelines for Treatment of Dengue 63. Carletti F, Castilleti C, Di Caro A, et al. Alkhurma hemorrhagic
Fever/Dengue Hemorrhagic Fever in Small Hospitals. London: fever in travelers returning from Egypt, 2010. Emerg Infect Dis.
World Health Organization. 1999. 2010;16(12):1979-1982.
43. Monath TP. Yellow fever: an update. Lancet Inf Dis. 2001;1:11-20. 64. Charrel RN, Coutard B, Baronti C, et al. Arenaviruses and
Seminal article. hantaviruses: from epidemiology and genomics to antivirals.
44. Mutebi JP, Barrett ADT. The epidemiology of yellow fever in Antivir Res. 2011;90:102-114.
Africa. Microbes Infect. 2002;4:1459-1468. 65. Paweska JT, Sewlall NH, Ksiazek TG, et al. Nosocomial out-
45. Quaresma JAS, Barros VLRS, Pagliari C, et al. Revisiting the break of novel arenavirus infection, Southern Africa. Emerg
liver in human yellow fever: virus-induced apoptosis in hepato- Infect Dis. 2009;15(10):1598-1602.
cytes associated with TGF-beta, TNF-alpha and NK cell activity. 66. Frame JD, Baldwin JMJ, Gocke DJ, et al. Lassa fever, a new
Virology. 2006;345:22-30. virus disease of man from West Africa. Clinical description and
46. Jentes ES, Poumerol G, Gershman MD, et al. The revised global pathological findings. Am J Trop Med Hyg. 1970;19:670-676.
yellow fever risk map and recommendations for vaccination, 67. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in West African
2010: consensus of the informal WHO working group on geo- sub-region: an overview. J Vect Borne Dis. 2007;44:1-11.
graphic risk for yellow fever. Lancet Inf Dis. 2011;11:622-632. 68. Kunz S. The role of the vascular endothelium in arenavirus
Seminal article. hemorrhagic fevers. Thromb Haemost. 2009;102:1024-1029.
47. Center for Disease Control and Prevention. Yellow fever. CDC 69. World Health Organization. Lassa fever. WHO Newsletter,
website. http://www.cdc.gov/yellowfever/healthCareProviders/ Geneva; 2005.
index.html. Accessed October 20, 2014. 70. Fichet-Calvet E, Rogers DJ. Risk maps of Lassa fever in West
48. Centers for Disease Control and Prevention. Brunette GW, ed. Africa. PLoS Negl Trop Dis. 2009;3(3):e388.
CDC Health Information for International Travel. Atlanta, GA: 71. Bonner PC, Schmidt WP, Belmain SR, et al. Poor housing qual-
Centers for Disease Control; 2012. ity increases risk of rodent infestation and Lassa fever in refugee
49. Monath T. Treatment of yellow fever. Antiviral Res. 2008;78:116-124. camps of Sierra Leone. Am J Trop Hyg. 2007;77(1):169-175.
50. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive 72. Curtiss N. Viral hemorrhagic fevers caused by Lassa, Ebola
surveillance of yellow fever vaccine 17D or 17DD-associated seri- and Marburg viruses. In: Pollard AJ, Finn A, eds. Hot Topics in
ous adverse events: systematic review. Vaccine. 2011;29:4544-4555. Infections and Immunity in Children. New York: Springer; 2006.
51. McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease 73. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective
associated with 17D-204 yellow fever vaccination: a report of 15 therapy with ribavirin. N Engl J Med. 1986;314:20-26. Seminal
cases. Vaccine. 2007;25:1727-1734. article.

Section05-O-ref.indd 2 1/20/2015 4:51:25 PM